EXHIBIT 99.1

HART and Mayo Clinic Confirm Dates for Collaborative

Large-Animal Bioengineered Organ Implant Surgeries

Holliston, MA, January 7, 2016 – Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today provided an update on large-animal studies being conducted with its co-development collaborator, Mayo Clinic.

Since the November announcement of positive results from large-animal studies of its esophageal, tracheal and bronchial implants, HART has conducted additional studies to advance its platform for those product candidates and to help shape the design of studies with Mayo Clinic. Initial surgeries in the Mayo Clinic collaboration have been scheduled for January 22 and February 2, 2016, with additional procedures to occur through mid-February.

Dennis Wigle, M.D., Ph.D., Associate Professor of Surgery and Chair of Thoracic Surgery at Mayo Clinic as well as HART Chief Medical Officer, Saverio La Francesca, M.D., will perform the implantation surgeries. Although originally anticipated to begin in December, the surgery schedule was adjusted due to scheduling conflicts amongst the study collaborators.

HART’s CEO, Jim McGorry, stated, “We are excited to team with Dr. Wigle and Mayo Clinic and to advance the development of our esophagus, trachea and bronchus organ implants. We also continue to perform additional research internally to further deepen our understanding of our implants and their use in varying applications. We remain committed to advancing our platform development toward our 2016 goals of filing with the FDA to initiate human clinical trials as well as pursuing compassionate use surgeries in humans.”

Saverio La Francesca, M.D., added, “We are conducting these studies to answer key scientific questions regarding regeneration and mechanism of action. The goal of these studies is to inform our IND filing with the FDA and appropriately translate these findings into human use.” 

HART’s management team will be in San Francisco to meet with investors next week, Monday, January 11^th through Wednesday, January 13^th. Jim McGorry will present at the Biotech Showcase Monday, January 11^th at 2:00 p.m. Pacific Time. His presentation will be webcast live and for replay.

About HART (http://www.harvardapparatusregen.com)

Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. Our first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine our technology platform with the goals of pursuing one or more compassionate use implantation surgeries and filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any HART products by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of HART products, including those pertaining to the airway or esophagus, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the our implant products, bioreactors, scaffolds and other devices and product candidates we pursue; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Twitter: Investor Relations @HART_IR_Team

StockTwits: @HART_Investor_Relations

Investor Relations:

Harvard Apparatus Regenerative Technology, Inc.

Tom McNaughton

Chief Financial Officer

774-233-7321

Catalyst Global LLC

David Collins, Tanya Kamatu

212-924-9800

hart@catalyst-ir.com